Melanoma is a malignant proliferative disease originated from melanocyte transformations, which are characterized by a high metastatic rate and mortality. Advances in Nanotechnology have provided useful new approaches and tools for antitumor chemotherapy. The aim of this study was to investigate the molecular mechanisms underlying chitosan nanoparticles containing S-nitroso-mercaptosuccinic acid (S-nitroso-MSA-CS)-induced cytotoxicity in melanoma cells. S-nitroso-MSA-CS induced concentration-dependent cell death against B16-F10 tumor cells, whereas non-nitroso nanoparticles (CS or MSA-CS) did not induce significant cytotoxicity. Additionally, melanoma cells were more sensitive to cell death than normal melanocytes. S-nitroso-MSA-CS-induced cytotoxicity exhibited features of caspasedependent apoptosis and it was associated with oxidative stress, characterized by increased mitochondrial superoxide production and oxidation of protein thiol groups. In addition, tyrosine nitration and cysteine S-nitrosylation of amino acid residues in cellular proteins were observed. The potential use of these nanoparticles in antitumor chemotherapy of melanoma is discussed.
Page 2 of 29 Molecular Pharmaceutics   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 3 Graphical 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 INTRODUCTION Skin cancer is the most common type of cancer in Caucasian populations, [1] and the clinical classifications are based on the tumor origin and divided into non-melanoma skin cancer and melanoma. [2] Melanoma arises from cumulative abnormalities in melanocytes in response to ultraviolet-induced DNA damage, resulting in genetic mutations that support their malignancy through stimulation of blood vessel growth, evasion of the immune response and apoptosis, tumor invasion and metastasis. [3] Specific gene mutations are associated with an increased risk of melanoma, e.g., the substitution of valine (V) to glutamic acid (E) at position 600 in the BRAF gene (BRAF V600E), which is reported in 40-50% of melanoma cases. [4] Early diagnosis of melanoma is crucial for the effectiveness of treatment and favorable prognosis of patients. Available tools for melanoma treatment include surgical excision, immunotherapy, radiotherapy, and chemotherapy. [5] Immunotherapy (ipilimumab) or targeted therapy (vemurafenib) are the main chemotherapeutic approaches used for the treatment of metastatic melanoma when the BRAF V600E mutation is expressed. [6] Antitumor drugs have serious side effects, including hypotension, neutropenia, gastrointestinal and skin dysfunctions, and hair loss. [6] Specifically, for the treatment of melanoma, toxic side effects described for vemurafenib include photosensitivity, follicular hyperkeratosis, maculopapular rash, arthralgia, QT prolongation, and others. [7] For ipilimumab, the most common side effects described include diarrhea, nausea, constipation, abdominal pain, vomiting, vitiligo and dermatitis, [8] although more deleterious side effects had already been described such as hepatitis, [9] enterocolitis, [10] pancreatitis and nephritis. [11] New approaches are emerging in the drug discovery field due to the recent advances in Nanotechnology, providing additional opportunities to overcome drug resistance and toxicity, which are considered the major limitations in melanoma chemotherapy. [12] These nanotechnological strategies involve the development of several types of nanostructured drug delivery systems focused on the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   5 improvement of the specificity and efficacy of chemotherapeutic drugs, increasing the drug concentration inside the tumor mass, and decreasing toxicity of chemotherapy. [13] Polymeric nanoparticles form colloidal systems, which are potentially useful for carrying drugs with low water solubility and/or controlling drug release, providing increased stability and drug delivery profile. [14] Therefore, chitosan, which is a biocompatible, nontoxic, and biodegradable polymer with pharmaceutical applications, has been widely used for nanoparticle preparation. [15] It is well known that nitric oxide ( NO) is involved in various physiological cellular processes such as differentiation and apoptosis. [16] At high concentrations, NO exhibit anticancer properties; [17] however, due to its short half-life in biological environments (1-5 s), it becomes difficult to reach these antitumor concentrations. [18] To increase their bioavailability and in vivo stability, low molecular weight molecules capable of acting as NO donors, such as S-nitrosothiols (RSNOs), have been developed. [19] Considering that NO-releasing polymeric nanomaterials are emerging as a promising strategy in cancer chemotherapy, [20] biocompatible chitosan nanoparticles (CS) were synthesized and used to encapsulate low molecular weight mercaptosuccinic acid (MSA), a thiol-containing small molecule. Free thiol groups on mercaptosuccinic chitosan nanoparticles (MSA-CS) were nitrosated to form S-nitroso-MSA-containing chitosan nanoparticles (S-nitroso-MSA-CS). S-nitroso-MSA belongs to the class of RSNOs and acts as a NO donor. S-nitroso-MSA-CS was previously synthesized and characterized and had its cytotoxicity screened in different cancer cells lines. [21] Additionally, the transdermal NO delivery in human skin upon dermatological application of S-nitroso-MSA-CS was demonstrated. [22] Here, we investigated the underlying mechanisms of cytotoxicity of Snitroso-MSA-CS in an in vitro melanoma model. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 6
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EXPERIMENTAL SECTION
Synthesis of MSA-CS and nitrosation to produce S-nitroso-MSA-CS
CS nanoparticles were prepared using an ionotropic gelation process. [23] Briefly, 0.1 g of CS was solubilized in 0.1 L of 1% acetic acid plus 66.7 mM MSA. Under magnetic stirring, 5.0 mL of 0.6 mg/mL sodium tripolyphosphate was added dropwise in 15 mL of MSA-CS suspension. The final mixture was stirred for 45 minutes at 25°C to form the aqueous suspension of CS (1.0 mg/L of CS) containing 7.5 mg/mL of MSA (which corresponds to 50 mM MSA). Control CS was prepared without the addition of MSA. The thiol groups of MSA-CS were nitrosated by reacting with an equimolar amount of sodium nitrite in acidified medium, as previous described. [24] This solution was homogenized, protected from light, incubated for 30 min, and used immediately in experiments. The formation of S-nitroso-MSA-CS was confirmed by the detection of S-NO characteristic absorption bands at 336 and 545 nm.
Cell culture and standard incubation conditions with NPs
Cell line B16-F10 was purchased from the Rio de Janeiro Cell Bank (BCRJ 0046) (murine melanoma), and Melan-A (murine normal melanocytes) was generously provided by Prof.
Miriam Galvonas Jasiulionis (UNIFESP) in 2015. Consequently, the authors performed no additional authentication. All cell lines were tested to be mycoplasma-free by indirect staining with Hoechst 33258 (Thermo Fisher Scientific, USA) and were used within 3 months of thawing the frozen stock. Cells were grown in DMEM (Dulbecco's Modified Eagle's medium) high glucose medium (Sigma-Aldrich, USA) pH 7.2, supplemented with 10% fetal bovine serum (Gibco, Invitrogen, USA), 100 U/mL penicillin and 100 µg/mL streptomycin, in a 5% CO 2 atmosphere at 37°C (Panasonic MCO-19AIC, Japan). For experiments, cells were detached, centrifuged (160×g for 10 minutes), and suspended in supplemented DMEM medium. B16-F10 cells (5.26×10 4 cells/cm 2 ) were added to microplates for 24 h for cell adhesion. After, S-nitroso-MSA-CS (20 and 40 µg/mL) was added and incubated for additional 24 h.
Cytotoxicity assays
The cytotoxicity of NPs was screened by the trypan blue dye exclusion assay in B16-F10 melanoma cells and melanocytes Melan-A. Compounds were added at increasing concentrations (5.0, 10, 20, and 40 µg/mL) and incubated for 24 h. After this, trypan blue was added 0.016% (w/v) and cells were counted using a Neubauer chamber. Additionally, the effects of modulators of cell death induced by S-nitroso-MSA-CS were evaluated by the MTT reduction test. Thus, after an incubation period, 0.25 mg/mL MTT was added and incubated for 4 h. Then, 0.1 mL of 10% SDS was added, incubated overnight, and plates were read at 570 nm/620 nm (Biochrom Asys Expert Plus Microplate Reader, Biochrom Ltd., UK). The modulators [50 µM Boc-D-FMK (Sigma-Aldrich, USA), 5 µM MY5445 (Tocris Bioscience, USA), 100 µM PTIO (Sigma-Aldrich, USA)] were pre-incubated 1 hour before the addition of the nanoparticles. Cell viability in both assays was calculated in relation to the control (absence of NPs), which was considered as 100%.
Lactate dehydrogenase (LDH) release
After a standard incubation, cells were detached and centrifuged (160×g for 10 minutes) and supernatants were kept at 4°C. LDH activity released by cells was determined through NADH oxidation measured using the LDH assay kit according to the manufacturer instructions (Labtest Diagnostica SA, Brazil). Triton X-100 (0.2%) was used as positive control. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60
Annexin V-FITC/PI double staining flow cytometry analysis
After a standard incubation, cells were detached, centrifuged (160×g for 10 minutes) and suspended in 50 µL of binding buffer [25] 
Active caspase 3
Caspase 3 was measured by flow cytometry using a monoclonal antibody against the active form. After a standard incubation, cells were fixed with 2% paraformaldehyde in PBS for 30 min and permeabilized with 0.01% saponin in PBS for 15 min at room temperature. Cells were then collected and incubated with 10 µL anti-active-caspase-3 monoclonal antibody conjugated with FITC #559565 (BD-Pharmingen, USA). After a 40-min incubation at 37 °C, the fluorescence emission was analyzed acquiring 10,000 events per sample using blue laser excitation (488 nm), dichroic mirror 502 LP, bandpass filter 530/30 and the FITC fluorescence channel with a FACSCanto II Flow Cytometer. Data analysis and graphs were completed using Flow Jo vX.0.7 software. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   9 Total protein −SH groups were quantified using 5,5′-dithiobis (2-nitrobenzoic) acid (DTNB).
Reduced protein thiol content
After a standard incubation, cells were detached and centrifuged for 10 min at 700×g. The pellet was treated with 0.2 ml of 6% trichloroacetic acid and centrifuged at 6000×g for 15 min to precipitate the proteins. This precipitate was suspended with 1 ml of 0.5 M potassium phosphate buffer pH 7.6 by vortexing. After the addition of 0.1 mM DTNB, absorbance was determined at 412 nm (UV-Visible Spectrophotometer UV-1800, Shimadzu, Japan). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 10 After a standard incubation, cells were fixed with 2% paraformaldehyde in PBS for 30 min and permeabilized with 0.01% saponin in PBS for 15 min at room temperature. Cells were then incubated overnight with the rabbit polyclonal anti-nitrotyrosine primary antibody 
Reactive oxygen species (ROS) production
Detection of cysteine S-nitrosylation and tyrosine 3-nitration
Statistical analyses
Values were obtained from at least three independent experiments run in triplicate. Data were expressed as the mean ± SEM, and statistical analyses were performed by a one-way analysis of variance (followed by a Tukey post hoc test) with significance defined as *p<0.05, **p<0.01, *** p<0.001. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
RESULTS
Enhanced and selective cytotoxicity of S-nitroso-MSA-CS in melanoma B16-F10 cells
The effects of S-nitroso-mercaptosuccinic acid containing chitosan nanoparticles (S-nitroso-MSA-CS) (Fig. 1A) on B16-F10 and Melan-A cell viability were screened by the trypan blue exclusion assay. S-nitroso-MSA-CS exhibited high cytotoxicity against the B16-F10 tumor cell line in a concentration-dependent manner after 24 h of incubation. Such cytotoxicity was higher in tumor cells than in normal melanocytes (Fig. 1B) . Additionally, non-nitroso MSA chitosan nanoparticles (MSA-CS), empty chitosan nanoparticles (CS), free S-nitroso-MSA, and MSA (in the same molar ratio used in Fig. 1B) were evaluated in B16-F10 cells and no significant cytotoxicity was achieved, showing the dependence of the nanoparticle structure ( Fig. 1c) . In flow cytometry, the frontal dispersion of the laser (forward scatter, FSC) gives information about the relative cell size and the lateral dispersion (side scatter, SSC) is related to granularity or complexity of the cell. S-nitroso-MSA-CS decreased cell size and increased the granularity of melanoma cells, defining a 'dead' population ( Fig. 1D) , which was dependent on concentration ( Fig. 1E) . Additionally, S-nitroso-MSA-CS induced the loss of normal morphology, membrane blebbing, cell shrinkage, emission of plasma membrane projections, and disruption. The loss of adhesion with the external matrix and neighboring cells was also observed (Fig. 1F ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
S-nitroso-MSA-CS induced apoptosis in melanoma cells
To obtain a better understanding of S-nitroso-MSA-CS-induced cell death, molecular markers of apoptosis and necrosis were evaluated. Annexin V-FITC/PI double staining flow cytometry revealed the predominance of double stained B16-F10 cells (annexin V + /PI + ), indicative of late apoptosis ( Fig. 2A ). Since the dot plot graph is one representative experiment, the quantification of apoptotic cells (annexin V + ), considering all replicates was presented ( Fig.   2B ). Additionally, the activation of effector caspase 3 during S-nitroso-MSA-CS-induced cell death was shown ( Fig. 2C and 2D) . The cell-permeable irreversible general caspase inhibitor Boc-D-FMK also prevented cell death ( Fig. 2E) , corroborating the participation of caspases.
The pre-incubation of B16-F10 cells with necrostatin-1 (Sigma-Aldrich #N9037) and IM-54 (Sigma-Aldrich #SLM0412), inhibitors of necroptosis and necrosis, respectively, did not prevent the S-nitroso-MSA-CS-induced cytotoxicity ( Fig. 2F and 2G ). In accordance, loss of plasma membrane integrity induced by S-nitroso-MSA-CS was not observed, as evaluated through the absence of LDH release by the cells (Fig. 2H) . Thus, S-nitroso-MSA-CS induced caspase-dependent apoptosis in melanoma cells. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Increased oxidative stress induced by S-nitroso-MSA-CS
A general view of the cellular reactive oxygen species (ROS) production can be achieved by the assessment of oxidized dichlorofluorescein (DCF) fluorescence emission. [26] Thus, B16- Fig. 3B . Considering the relative lack of specificity of this fluorophore to identify a specific free radical type, a kinetic measurement of ROS production elicited by S-nitroso-MSA-CS (dashed lines) with CM-H 2 DCFDA was performed for 120 minutes in the presence of catalase conjugated with polyethylene glycol (PEG-CAT, solid lines) (Fig. 3C) . The quantification of DCF fluorescence emission at 120 minutes revealed that part of the DCF oxidation at 20 µg/mL S-nitroso-MSA-CS was attributed to the peroxide production but at 40 µg/mL S-nitroso-MSA-CS PEG-CAT did not suppress the emission of fluorescence (Fig. 3D) , indicating that the radical production profile is different depending on the NPs concentration. Since H 2 O 2 can be formed by dismutation of superoxide anions produced by mitochondria, we also evaluated the mitochondrial superoxide generation after a 24 h incubation with NPs using MitoSOX™ Red. As expected, S-nitroso-MSA-CS also 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 16 increased the generation of superoxide anion radicals by mitochondria in a concentration dependent fashion ( Fig. 3E and 3F) . Antimycin A, an inhibitor of the mitochondrial respiratory complex III [27] was used as positive control (Fig. 3E, dotted line) . This increased radical production induced by S-nitroso-MSA-CS was accompanied by oxidation of the thiol group of proteins (Fig. 3G ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Page 17 of 29 Molecular Pharmaceutics   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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Cysteine S-nitrosylation and tyrosine nitration promoted by S-nitroso-MSA-CS
The incubation of B16-F10 melanoma cells with S-nitroso-MSA-CS (20 and 40 µg/mL) resulted in an increased formation of 3-nitrotyrosine ( Fig. 4A ) and S-nitrosocysteine (Fig. 4B) in a concentration dependent manner. To evaluate whether these observed effects were due to NO released by S-nitroso-MSA-CS, cells were pretreated with the NO scavenger PTIO (Fig.   4C ) and with an inhibitor of cyclic GMP phosphodiesterase MY5445 (Fig. 4D ). Both 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 modulators were not able to change the cytotoxicity exerted by S-nitroso-MSA-CS, which provided strong evidence that the protein modifications were not promoted by free cytosolic NO released from the nanoparticles. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 20
DISCUSSION
The cytotoxicity of NO donors was described in different tumor cell lines, including ovarian cancer, [28, 29] lung carcinoma, [30] breast adenocarcinoma, [31] hepatocellular carcinoma [32] neuroblastoma [33] and squamous cell carcinoma of the head and neck. [34] Such effects were associated with the inhibition of cell proliferation and induction of apoptosis. [35] In B16-F10 melanoma cells, organic nitrate NO donors inhibited their metastatic potential, and DETA/NO NO donors reversed the resistance to chemotherapeutic agents, including doxorubicin. [36] Additionally, organic nitrate NO donors prevented the formation of melanoma cell lung nodes in a murine melanoma in vivo model. [37] These reports suggest the therapeutic potential use of NO donor nanomaterials in many types of cancer antitumor chemotherapy, including melanoma. Here, a nanostructured system containing NO and Snitroso-MSA-CS exhibited cytotoxicity against B16-F10 melanoma cells with no significant cytotoxicity in normal melanocytes.
The mechanisms of cell death elicited by NO donors depend on several factors, such as cell type and tumor stage. Sustained NO production could act as a pro-apoptotic signal by activating caspases [38] through its effect on mitochondria [39, 40] or by upregulation of death receptor expression and their sensitization to death ligands, as Fas-L (Fas ligand), TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) and TNF-α (tumor necrosis factorα). [41] Our data demonstrated that the cytotoxicity induced by S-nitroso-MSA-CS in melanoma cells is through caspase-dependent apoptosis.
It is well established that NO stimulates the soluble guanylyl cyclase resulting in an increase of intracellular cGMP, [42] whereas cGMP phosphodiesterase leads to a decrease. [43] The cGMP phosphodiesterase inhibitor, MY-5445, increases the intracellular cGMP levels and thus mimics the NO effect, [44] but it did not alter the cytotoxicity of S-nitroso-MSA-CS, as well as the NO scavenger PTIO, despite the detection of NO-protein adducts as discussed 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   21 below. These data suggest that these nanoparticles probably do not act as a NO releasing prodrug.
Reactions between NO and −SH groups of protein cysteine residues lead to Snitrosylation, which is an important and reversible post-translational modification able to regulate the activity and function of many proteins and cellular processes. [45] S-nitroso-MSA-CS increased cysteine S-nitrosylation and tyrosine nitration in melanoma cells. Probably the S-nitroso groups of S-nitroso-MSA-CS were transferred directly to free thiol groups of proteins through S-(trans)nitrosylation. In agreement, the occurrence of S-(trans)nitrosylation without release of free NO by RSNOs was previously proposed. [46] It is well known that the oxidation of protein thiol groups in mitochondrial membranes is related to mitochondrial permeabilization and release of pro-apoptotic proteins to the cytosol, triggering cell death. [47, 48] S-nitrosylation induced by S-nitroso-MSA-CS in melanoma cells was accompanied by oxidative stress characterized by H 2 O 2 and mitochondrial superoxide overproduction, and by nitration of cellular proteins. In this regard, mitochondrial dysfunctions elicited by NO donors associated with increased superoxide production have been described. [49] Additionally, ruthenium nitrosyl complexes inhibited mitochondrial respiration in hepatocarcinoma cells, resulting in ATP depletion, ROS production, and cell death. [50] Increased superoxide production in mitochondria may occur due to nitration and inactivation of manganese-dependent superoxide dismutase [51] and/or inhibition of the respiratory chain. [52] These superoxide can react with NO generating peroxynitrite that nitrates -OH groups in tyrosine residues irreversibly, and the adduct 3nitrotyrosine is widely used as a nitrosative stress marker. [53] In summary, we presented here the cytotoxic effects of S-nitroso-MSA-CS on B16-F10 melanoma cells. Such effects were selective to tumor cells when compared to normal melanocytes and dependent on the entire nanoparticle composition; only CS, free MSA or 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 22 free S-nitroso-MSA did not exhibit significant cytotoxicity. Additionally, the investigation of molecular mechanisms of cytotoxicity revealed that S-nitroso-MSA-CS induced an apoptotic cell death profile, dependent on caspase activation, and associated with a cellular and mitochondrial oxidative stress. Together these results point to the potential use of S-nitroso-MSA-CS as an antitumor chemotherapy of melanoma.
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